Form 4: Elanco Animal Health CEO Jeffrey Simmons Acquires Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Summary

• On June 14, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired deferred stock units.
• These deferred stock units represent the right to receive one share of Elanco's common stock or the cash equivalent.
• The transaction involved 153.5907 deferred stock units at a price of $18.03, resulting in a holding of 2,114.2755 deferred stock units.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction related to executive compensation. It doesn't inherently indicate positive or negative performance, but rather a routine part of executive pay.

Positives

• The acquisition of deferred stock units by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Industry Context

Executive compensation in the form of stock and deferred stock units is a common practice in the animal health industry to align management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO aligns his interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates